Cancer immunotherapy, also known as monoclonal antibody therapy (mAb) and adoptive cell transfer (ACT) therapy for immune cells, is a way of treating cancer by regulating an immune response. In a range of tumor types, mAb treatment, which is based on promoting T cell function by inhibiting or activating immunoregulatory pathways, has produced notable therapeutic responses. Nevertheless, not all patients are able to sustain a robust immunological response after therapy. Finding predictive biomarkers is crucial in order to choose patients who will benefit from the therapy. To investigate immunological and tumor-immune interactions at the single-cell level, a new approach is needed due to the complexity of the tumor microenvironment and the dynamic nature of the immune response.
Protein is normally produced or released in numerous, brief pulses, and in low quantities. Protein is an important chemical involved in a variety of physiological functions in cells. Because there are no effective PCR-like amplification methods for single-cell proteomics, a variety of analytical methods are used to assess a variety of critical factors, such as immunological diversity, intratumoral heterogeneity, and intercellular communication.
For more: single cell proteomics